Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BioGeneric Pharma
10th of Ramadan Industrial City, Egypt
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
BioGeneric Pharma produces and markets several commercialized biopharmaceuticals, focusing on biosimilars, recombinant proteins, small molecules, and vaccines, targeting markets in Africa, the Middle East, and EMEA. Approved products in Canada (via BGP Pharma ULC) include widely used drugs such as pregabalin, gabapentin, amlodipine, atorvastatin, and more.
- Therapeutic areas
- ImmunologyEndocrinologyPsychiatryInfectious DiseasesHematologyOncologyNeurology
- Modalities
- Therapeutic recombinant proteinVaccineBiosimilarSmall moleculeMonoclonal antibodyHormoneColony-stimulating factors
- Industry
- Biotech
02
Partnerships
Amotyop Biotech CompanyPharco CorporationBioGeneric Ltd. (USA)
Beyond the preview
Go deeper on BioGeneric Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioGeneric Pharma.